Skip to content
Search

Latest Stories

JLR announces partial shut down at Castle Bromwich plant

THE non-availability of key materials due to Covid-19 has forced Jaguar Land Rover to partially shut down production at its Castle Bromwich factory until Christmas.

Production of JLR’s XE and XF cars stopped earlier this week and will not restart for two weeks, the company said. However, production of Jaguar F-Type continues at the factory.


The West Midlands factory employs about 2,500 workers.

A JLR spokeswoman has said that the shortage was not caused by the congestion at England’s ports, which forced the Japanese carmaker Honda to stop production this week.

“As part of its usual business practice, Jaguar Land Rover regularly adjusts its production schedules. Whilst we have strong customer demand, we have made changes to our production schedule in Castle Bromwich due to temporary supplier constraints. We are working with the supplier to resolve this and minimise impact on customer orders," said a JLR spokeswoman.

Companies across the UK are struggling with delays to parts and finished products amid delays at the main British container ports, the rush to import products for Christmas, and global issues in the shipping industry, reported The Guardian.

The automotive industry, including JLR, has been outspoken in its opposition to the tariffs and regulatory barriers that would immediately hit them if no deal Brexit happens.

India's Tata Group-owned JLR was forced to shut down its factories in April and May due to the coronavirus pandemic.

The Guardian previously revealed that JLR was only planning to use a small proportion of its capacity at Castle Bromwich, with about 3,500 each of the XE and XF due to be produced until the end of March, according to plans that did not take into account the latest shortages.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less